Although they are mainly used to treat allergic asthma, coronary artery disease, and other diseases [173], we expect that the early clinical transformation of TBXA2R signaling pathway therapy will be able to improve the prognosis of HPS-PF patients. This evidence concerns the gene TBXA2R and pemphigus foliaceus.